Early-stage – Page 2

Biogen and Ionis Discontinue ALS Drug Development Following Unsuccessful Early Trials

1 year ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Biogen, Discontinuation (procedure), Drug Development, Early-stage, Ionis, nervous system disorder, research

Biogen, Ionis, ALS, drug development, early-stage trial, disappointing results, discontinuation, neurological disorder, treatment research.

Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC

2 years ago talkbio0Tagged Alecensa, ALINA, ALK gene, ALK Positive, Approved, Cessation of life, disease recurrence, Early-stage, genentech, Guidelines, Immunologic Adjuvants, Inhibitor, NCCN, Non-Small Cell Lung Carcinoma, Roche (company), United States Food and Drug Administration

Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines

FDA Approves BrainStorm’s Phase IIIb Trial Design for NurOwn in Early-Stage ALS

2 years ago talkbio0Tagged Agreement, Amyotrophic Lateral Sclerosis, BrainStorm Cell Therapeutics, Early-stage, NurOwn, SPA, Special Protocol Assessment, Trial Phase 3B, United States Food and Drug Administration

BrainStorm Cell Therapeutics, NurOwn, Phase IIIb trial, Special Protocol Assessment (SPA), FDA agreement, Early-stage ALS, Amyotrophic Lateral Sclerosis (ALS)